Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01094717 · ClinicalTrials.gov registry record · NA
Acitretin or Tazarotene Gel and Excimer Laser for Treatment of Psoriasis
A NA study, sponsored by University of Utah.
- Terminated
- Registry status
- NA
- Development phase
- 13
- Enrollment target
NCT01094717 is a NA study that was terminated before completion, run by University of Utah. The registered enrollment target is 13 participants.
The verdict
NCT01094717, a NA study, was terminated before completion, sponsored by University of Utah.
- TERMINATED
- Registry status
- NA
- Development phase
- 13 participants
- Enrollment target
Study Summary
This is a randomized, double-blind study of excimer (308-nm UVB) laser added to either tazarotene 0.1% gel or acitretin 25 mg daily for plaque psoriasis. The primary objective of this study is to compare the improvement of psoriatic plaques with and without excimer laser (308-nm UVB) treatment, applied in a randomized and blinded fashion, in subjects on acitretin 25 mg or tazarotene gel 0.1% QD.
Interventions
- DEVICE Excimer laser
- DRUG Acitretin 25Mg Oral Capsule
- DRUG Tazarotene 0.1% Gel,Top
- DEVICE Sham excimer laser
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 13 participants |
| Start Date | 2010-01 |
| Est. Completion | 2011-10 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01094717
The ClinicalTrials.gov registry entry for NCT01094717 describes a study currently listed as terminated, categorized as NA. The registered enrollment target is 13 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Utah, which has 818 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Excimer laser is the first listed.
NCT01094717 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01094717 about?
NCT01094717 is a clinical study titled "Acitretin or Tazarotene Gel and Excimer Laser for Treatment of Psoriasis". This is a randomized, double-blind study of excimer (308-nm UVB) laser added to either tazarotene 0.1% gel or acitretin 25 mg daily for plaque psoriasis. The primary objective of this study is to compare the improvement of psoriatic plaques with and without excimer laser (308-nm UVB) treatment, app...
What is the current status of trial NCT01094717?
This trial is currently terminated. It is a NA study. The enrollment target is 13 participants. The study started on 2010-01. Estimated completion is 2011-10.
What interventions are being tested in trial NCT01094717?
The interventions under investigation include: Excimer laser (DEVICE), Acitretin 25Mg Oral Capsule (DRUG), Tazarotene 0.1% Gel,Top (DRUG), Sham excimer laser (DEVICE).
Who is sponsoring clinical trial NCT01094717?
This trial is sponsored by University of Utah, which has 818 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.